Cancel
Adaptimmune
Adaptimmune Employees
11 people indexed:
-
9hzh6s.61hv53v64@ykhkjb65xgk.b26 Sign up to see email
-
05lf4k.bbl8wz7@881v4z7jfk7.2v2 Sign up to see email
-
Dennis Williams, Pharm.D.
Senior Vice President, Late Stage Development
5x6jgk.jfy76vq1.q529y.4@zx6q358f9f0.7g4 Sign up to see email6b7v9q.g9fqxy40.61y2f.f@k2g2ygbgqjb.q4z Sign up to see email -
969ww1.25k30.w.h@zgq8zw86k8z.s73 Sign up to see email
-
qx0sj.k543@5y2q8flbr8r.x3j Sign up to see email
-
Helen Tayton-Martin, Ph.D., M.B.A.
Chief Business & Strategy Officer
x9788.q67f1qxfjj356.k6.q.0.z.2@41371wkxx72.fvs Sign up to see emailvw1gw.z46gjjwxs8f02.61.w.9.8.z@786997gv997.s7x Sign up to see email -
Joanna Brewer, Ph.D.
Chief Scientific Officer
g8ksy2.85yx8x.6z.f@5kyxxxf52qs.g3s Sign up to see email462127.97323k.yz.9@s1g2fz19421.lzx Sign up to see email -
w545.z532y0@k0yxxssyqk2.v8z Sign up to see email
-
Karen Chagin, M.D.
SVP Early-Stage Development
f6w2v.xfqwsw.8.5@zj6598bx3xx.6zf Sign up to see email5691b.xz7vj3.v.0@41q5sf241yl.yb9 Sign up to see email -
j976v.0x5jw@lzl0w9fbj3l.l5f Sign up to see email
-
k5hk9vz.65z1xq6x@2g6j6fx052h.5k4 Sign up to see email
Adaptimmune Company Information
Adaptimmune is a biotechnology firm engaged in developing T-cell-based therapies aimed at treating cancer. The company utilizes a proprietary cell therapy platform to engineer a patient’s own cells to target and fight cancer, specifically solid tumors. Adaptimmune has recently submitted its first Biologics License Application (BLA) to the FDA for a T-cell therapy designed for solid tumors. The company’s pipeline includes multiple engineered T-cell therapies, each targeting different solid tumors. Adaptimmune’s manufacturing process involves leukapheresis and the delivery of affinity-enhanced TCRs (T-cell receptors), ensuring the production of therapeutic candidates under Good Manufacturing Practices (GMP). The company has established partnerships with several notable entities, including Alpine Immune Sciences, Genentech, and MD Anderson Cancer Center, to enhance its platform capabilities and accelerate the development of its products. Additionally, Adaptimmune supports patient organizations financially and engages in educational and awareness initiatives to further support cancer treatment advancements. The company operates out of offices in Oxfordshire and Stevenage in the UK, and Philadelphia in the US, with a dedicated GMP vector manufacturing space in the UK through an agreement with Cell and Gene Therapy Catapult.
Report inaccurate information
Report inaccurate information
